

**Date and Time: Tuesday 20th November 2012
10:00 – 16:30**

Minutes: Confirmed

**Guideline Development Group Meeting Diabetes in children and young people
guideline update**

Place: *Royal College of Obstetricians and Gynaecologists
London*

Present: Jerry Wales (Chair) (JW)
 Francesca Annan (FA) (Present for notes 1 – 16)
 Jo Dalton (JD) (Present for notes 1 – 16)
 Jacqueline Double (JDo) (Present for notes 1 – 16)
 Sarah Eaton (SE) (Present for notes 1 – 16)
 Julie Edge (JE) (Present for notes 1 – 16)
 Nikhil Gokani (NG) (Present for notes 1 – 16)
 William Lamb (WL) (Present for notes 1 – 16)
 Claire Pesterfield (CP) (Present for notes 1 – 16)

In attendance:

NCC-WCH staff:		
Zosia Beckles (ZB)		(Present for notes 1 – 16)
Paul Jacklin (PJ)		(Present for notes 1 – 16)
Juliet Kenny (JK)		(Present for notes 1 – 16)
Hugh McGuire (HM)		(Present for notes 1 – 16)
Moira Mugglestone (MM)		(Present for notes 1 – 16)
Stephen Murphy (SM)		(Present for notes 1 – 16)
NICE attendees:		
Sarah Dunsdon (SD)		(Present for notes 1 – 8)

Observers:

None		
------	--	--

Notes

1. JW welcomed the group to the first meeting of this guideline development group (GDG) and introduced himself as the Chair. JW asked each GDG member to introduce themselves. Apologies were received from Emma Chambers (Patient and Public Involvement Programme (PPIP) at NICE).
2. JW gave a presentation on the roles and responsibilities of GDG members as part of the guideline development process. After the presentation, the group had an opportunity to ask questions.
3. JK explained the importance of declarations of interest (DOIs) and clarified the terms used in the National Institute for Health and Clinical Excellence (NICE) DOI form. All the GDG members and other attendees were asked to summarise their interests for the group.

JW

Non-personal pecuniary:

Sheffield Children's Hospital Foundation Trust clinical research faculty received funding from Merck Sharp & Dohme (MSD) and Parexel via the Medicines for Children Research Network (MCRN) for JW's participation in research into the pharmacokinetics of novel

medications for type 2 diabetes (both projects yet to start), from Novo Nordisk for JW's participation in a Paediatric Investigation Protocol for a new long-acting insulin for type 1 diabetes (historical declaration only, no on-going interests), and from 9 companies manufacturing medications or equipment for diabetes (Abbott, Bayer, LifeScan (Johnson and Johnson), Lilly, Novo Nordisk, Owen Mumford, Roche, Sanofi, and Ypsomed) to support the Yorkshire Regional Paediatric Diabetes Network meeting 2011 (historical declaration only, no on-going interests).

Personal non-pecuniary:

Member of the British Society for Paediatric Endocrinology and Diabetes (BSPED), Diabetes UK, the European Society for Paediatric Endocrinology (ESPE) and the International Society for Paediatric and Adolescent Diabetes (ISPAD); published and lectured on bariatric surgery in young people; joint chief investigator on a project funded by Diabetes UK but receives no money directly and has no managerial responsibility for the budget.

FA

Personal pecuniary:

Invited chair at International Diabetes Federation (IDF) World Congress, Dubai 2011 and received funding from Novo Nordisk, Roche and Sanofi towards travel and accommodation expenses; invited speaker at the ISPAD annual meeting 2012 and received funding from Roche towards accommodation expenses.

Non-personal pecuniary:

Co-applicant for the following HTA-funded trials: Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE), randomised controlled trial of continuous subcutaneous insulin infusion compared to multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes (Subcutaneous Insulin, Pumps or Injections (SCIPI)).

Personal non-pecuniary:

Member of British Dietetic Association, Diabetes Management & Education Group (DMEG), Diabetes UK, ISPAD, Sports Dietitians UK; regular teaching commitments about nutritional management of diabetes, and exercise and diabetes at University of York, University of Warwick, Coventry University, Birmingham Children's Hospital; contributed to ISPAD guidelines on nutritional management and exercise; written articles on exercise and diabetes management and nutritional management of diabetes for Complete Nutrition and Diabetes Care for Children & Young People; presentations at national and international meetings on exercise and diabetes management; reviewed patient information content of Diabetes UK publications and pharmaceutical company literature (Lilly and Roche).

JD

Personal pecuniary:

Current post as paediatric diabetes specialist nurse funded by a diabetes charity within the Royal London Hospital.

Personal non-pecuniary:

Member of the GDG for the 2004 NICE guideline on type 1 diabetes; member of the Royal College of Nursing (RCN), ISPAD, Primary Care Diabetes Society (PCDS) and professional member of Diabetes UK.

JDo

Personal pecuniary:

Honorarium from NHS Diabetes as Chair of national Parent Reference Group; attended Friends For Life conferences where hospitality was provided by commercial sources unknown to JDo; noted that previously declared personal pecuniary interest (funding Johnson and Johnson to attend a conference) not relevant as it occurred more than 12 months before appointment to the GDG.

Personal family interest:

Husband received travelling expenses from Children with Diabetes (a US not-for-profit organisation) to attend a Family Conference in the USA.

Personal non-pecuniary:

Spoke for NHS Technology Adoption Centre (NTAC) and NHS Diabetes; ran workshops on schools, advocacy and mother's emotional needs; member of Diabetes UK and JDRF; director of INPUT (a patient-run organisation that advocates for access to insulin pumps and diabetes technology in the UK); member of UK Children with Diabetes Advocacy Group.

SE

Personal non-pecuniary:

Attended GP education meetings funded by, Ashfield In2 Focus, Bayer Healthcare, Boehringer Ingelheim, HRA Pharma, Napp Pharmaceuticals, Pfizer, Reckit Benckiser; professional member of Diabetes UK, volunteer for Diabetes UK children's care events; member of team (also involving Diabetes UK, University of Huddersfield and University of York) planning a conference on new developments in diabetes management in primary care.

JE

Personal pecuniary:

Honoraria for writing on type 1 diabetes for the British National Formulary for Children.

Non-personal pecuniary:

JE holds managerial responsibility for departmental funding from Oxford Medical Diagnostics for a research project on a device not directly linked to any of the topics in the scope, from Aventis, Novo Nordisk, and Roche for sponsorship of educational meetings, and from the British Heart Foundation, Diabetes UK, JDRF, National Institute for Health Research Comprehensive Clinical Research Network (NIHR CCRN) via the Comprehensive Local Research Networks (CLRN) and Thames Valley Diabetes Research Network (TVRN) for the following research projects for which JE is the local principle investigator: Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT); Diabetes Genome Anatomy Project (DGAP); and studies about insulin for diabetes including a randomised controlled trial of continuous subcutaneous insulin infusion compared to multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes (SCIPI).

Personal non-pecuniary:

Involved over many years in research on the management of diabetic ketoacidosis; lectured and prepared guidelines on diabetic ketoacidosis; member of Association of Children's Diabetes Clinicians (ACDC), BSPED, Diabetes UK and ISPAD.

NG

Personal non-pecuniary:

Supporting member of Diabetes UK and member of its groups and committees; contingent PhD candidate in public health and law; member of the National Diabetes Audit Partnership Board.

WL

Personal pecuniary:

Honoraria from Practical Diabetes for writing an article about adolescent diabetes and from Medtronic Ltd for lecturing on continuous glucose monitoring.

Personal non-pecuniary:

Professional member of Diabetes UK; member of ACDC, BSPED and ISPAD; volunteer for Diabetes UK and JDRF; associate editor of Clinical Diabetes; attended meetings supported by various industry sponsors unknown to WL as part of continuing professional development.

CP

Non-personal pecuniary:

Addenbrookes Charitable Trust will receive honoraria from Abbott, Animas, Roche and Medtronic for CP presenting clinical case studies regarding diabetes care and writing an article about an education event (sports day) for Diabetes Care of Children and Young People (due to be published soon) and an article about management of neonatal diabetes for Diabetes Management (publication date to be confirmed).

Personal non-pecuniary:

Volunteer for Diabetes UK; IDF young leader programme mentor; wrote article about parental attitudes to a closed-loop blood glucose trial for Diabetes Technology and Therapeutics (2010).

No other declarations of interest were received from the GDG members or the other attendees. It was agreed that no interests declared at the meeting or previously warranted exclusion of any GDG members from discussions of evidence or formulation of recommendations at the meeting.

Declarations are kept on record at the NCC-WCH and will be published in the full guideline.

4. SD presented an overview of the work of NICE, and the role of clinical guidelines. After the presentation, the group had an opportunity to ask questions.
5. In EC's absence, JW gave a presentation on the PPIP at NICE. After the presentation, the group had an opportunity to ask questions.
6. JW presented the topics that would be covered in the guideline scope. After the presentation, the group had an opportunity to ask questions.
7. MM gave a presentation on developing review questions. MM then introduced the GDG to the draft review questions, after which the group discussed and finalised the review questions.
8. MM presented an overview of study designs and their relevance to review questions. After the presentation, the group had an opportunity to ask questions.
9. HM presented the draft review protocol for the metformin monotherapy for type 2 diabetes review question. The group then discussed and finalised the protocol.
10. ZB gave a presentation to explain the method for identifying evidence, including the process for developing a search strategy based on the protocol and the process for sorting the results identified from bibliographic databases. After the presentation, the group had an opportunity to ask questions.
11. HM presented the process for reviewing evidence and explained the GRADE approach to reviewing evidence. After the presentation, the group had an opportunity to ask questions.
12. HM presented the draft review for the question on metformin monotherapy for type 2 diabetes (the list of excluded studies, the evidence tables, the evidence profiles and the evidence summary). The group had an opportunity discuss the evidence presented and then agreed principles for completing both reviews.
13. JK gave a presentation to explain how to link evidence to recommendations. The group had an opportunity discuss this, and to ask questions.
14. HM led the group through the process of interpreting the evidence and drafting recommendations for metformin monotherapy for type 2 diabetes review question. Notes were made live on screen.
15. ZB presented the draft review protocol for the multiple daily injections for type 1 diabetes review question. The group then discussed the protocol and notes were made live on screen.
16. There was no other business. JW thanked the participants for attending and closed the meeting.

Date, time and venue of the next meeting

Tuesday 18th December 2012, 10:00 – 16:30 at the Royal College of Obstetricians and Gynaecologists, London